BiotechTube
EPOK Therapeutics

EPOK Therapeutics

San Diego, United States· Est.
epoktherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

EPOK Therapeutics is a newly formed, private biotech focused on developing next-generation biologic therapies for metabolic disorders, particularly those related to chronic kidney disease (CKD). The company leverages over two decades of antibody engineering expertise to create targeted therapies for anemia and phosphate wasting disorders. Its initial pipeline features two lead preclinical candidates: EPRA-0322 for anemia and KLOT-1123 for phosphate-related disorders. As a pre-revenue, preclinical-stage company, EPOK's strategy centers on advancing these programs through development to address significant unmet needs in nephrology and metabolic disease.

Metabolic DiseasesRenal DiseaseChronic Kidney Disease (CKD)

Technology Platform

Antibody engineering platform for developing agonist and antagonist antibodies with reduced off-target activity, enhanced safety, and optimized dosing/production efficiency.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Large and growing patient populations with CKD-associated anemia and phosphate disorders represent multi-billion dollar markets with documented unmet needs for safer, more convenient therapies.
A successful next-generation anti-FGF23 antibody could address both rare genetic disorders and the broader CKD population.
The company's platform, if validated, could be applied to other metabolic and inflammatory diseases.

Risk Factors

High preclinical and clinical development risk; unproven platform and novel candidates.
Significant funding risk as a private, early-stage company.
Intense competition from established therapies and novel agents in late-stage development for both target indications.
Lack of disclosed leadership or investors raises questions about operational capability and financial runway.

Competitive Landscape

The anemia space is dominated by ESAs (Amgen, Johnson & Johnson) and newer HIF-PH inhibitors (FibroGen/AstraZeneca, GSK). The phosphate disorder space features an approved anti-FGF23 antibody (burosumab) for XLH and several competitors in development. EPOK's differentiation hinges on demonstrating superior safety and dosing convenience versus these established and emerging therapies.

More companies in Biologics / Biosimilars →More companies in United States →